[The role of fat tissue in development of metabolic disorders in patients with diabetes mellitus type 2 and obesity].
OBJECTIVE
To specify changes in clinicolaboratory parameters in reduction of obesity in patients with diabetes mellitus type 2 (DM-2).


METHODS
Antropometry, densitometry of fat tissue (FT) were made and parameters of fat and carbohydrate metabolism (lipidogram, glycated hemoglobin, immunoreactive insulin), FT secretory activity (leptin, adiponectin, TNF-alpha) were studied in 75 obese DM-2 patients. After the above primary examination all the patients were randomized into 2 groups: group 1 (n = 55) received xenical (120 mg 3 times a day) and kept moderate hypocaloric diet; group 2 (n = 20) received only the above diet therapy. Active treatment lasted 24 weeks.


RESULTS
In addition to symptoms of metabolic syndrome (MS) the patients were found to have secretory disturbances of FT activity: elevation of leptin and TNF-alpha levels, subnormal adiponectin. These alterations directly correlated with body mass, FT mass gain, increase in waist circumference. Hyperleptinemia, hyperinsulinemia and hypoadiponectinemia were considered as markers of insulin resistance (IR) and related conditions. Xenical promoted a significant weight loss resulting in a positive trend in the parameters of adipokines, fat and carbohydrate metabolism, in reduction of IR.


CONCLUSIONS
Xenical is beneficial for patients with DM-2 and obesity because it improves metabolic processes.
Demidova
T Iu
TIu
Selivanova
A V
AV
Ametov
A S
AS
D052242:Adiponectin / Q000032:analysis / Q000378:metabolism; D000273:Adipose Tissue / Q000033:anatomy & histology / Q000378:metabolism*; D000886:Anthropometry; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D031204:Caloric Restriction; D050260:Carbohydrate Metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000097:blood / Q000276:immunology; D007333:Insulin Resistance; D007783:Lactones / Q000494:pharmacology / Q000627:therapeutic use*; D020738:Leptin / Q000032:analysis / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000175:diagnosis; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy*; D000077403:Orlistat; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000378:metabolism
D052242:Adiponectin; D019440:Anti-Obesity Agents; D015415:Biomarkers; D006442:Glycated Hemoglobin; D007328:Insulin; D007783:Lactones; D020738:Leptin; D008055:Lipids; D000077403:Orlistat; D014409:Tumor Necrosis Factor-alpha